Replies to post #58081 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Your interpretation seems correct.

One of the big features of Alz drugs is extremely high failure rate - 99% failure - as such investors are skeptical about any early success - which seems short lived - that is reflected in the low valuation.

That is is one of the reasons why market is looking for 12 and 26 weeks data to get better idea on efficacy.

Company probably is looking to hedge bets by looking at alternative such as 3-71 - I consider as a better strategy.

[georgejjl]

DOLPHY

Celegene sold hundreds of millions of dollars worth of thalidomide for the treatment of cancer before it started selling Revlimid, a derivative of thalidomide, by the billions of dollars for the treatment of cancer specifically multiple myeloma.

It is almost without a doubt that Anavex3-71 will follow Anavex 2-73 as a treatment for Alzheimer's and other diseases and conditions such as Parkinson's, Huntington's, ALS, epilepsy, etc., etc., etc.

Good luck and GOD bless,

George

[JB3729]

If 3 71 is better, why are they wasting time on furthering trials on 2 73?

Nobody will know which drug is better until they both complete trials. One may work better for some diseases while the other works better on other diseases.

Anavex had to develop A2-73 or risk losing their rights to it -

Anavex (like most cash-strapped early-stage biotech companies) was not in good financial shape following the 2008 recession and may have been on the verge of failing to meet the obligations set forth in their agreement - and therefore on the verge of loosing all rights related to the patents. In the 2012 addendum, paragraph 2.1 is replaced with:

Assignee shall have invested, by December 31, 2017, at least $1,000,000 in the development and patenting of the subject matter of Article I, paragraph 1.1. For clarity the "development and patenting of the subject matter of Article I, paragraph 1.1" shall be termed the "Project"

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121027856